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OBJECTIVES: A growing body of evidence indicates that patients with sessile serrated adenoma/polyp (SSA/P) and traditional
serrated adenoma (TSA) are at risk for subsequent malignancy. Despite increasing knowledge on histological categorization of
serrated polyps (SPs) data are lacking on the actual prevalence and the association of each SP subtype with advanced colorectal
neoplasia.
METHODS: We prospectively determined the prevalence of different SP subtypes and evaluate the association with synchronous
advanced neoplasia in asymptomatic average-risk subjects undergoing first-time colonoscopy. All retrieved polyps were
examined by two independent pathologists. Serrated lesions were classified into hyperplastic polyps (HP), SSA/P (without and
with cytological dysplasia, SSA/P/DIS), and TSA, and were screened for BRAF and K-ras mutations.
RESULTS: Among 258 polyps detected in 985 subjects, the proportion of SSA/P and TSA was 8.9% and 1.9% with an overall
prevalence of 2.3% and 0.6%, respectively. SSA/Ps were small without significant difference in their location between proximal
and distal colon; TSA were predominantly left-sided. BRAF mutation was common in SSA/Ps and K-ras mutation was present in
all TSA. Independent predictors of advanced neoplasia were male sex (odds ratio (OR)¼ 2.0, 95% confidence interval (CI)
1.0–4.0), increasing age (OR¼ 4.5, 95% CI 1.5–13.4 for 50–69 years and OR¼ 9.9, 95% CI 3.1–31.5 for 470 years), current
smoking (OR¼ 2.0, 95% CI 1.3–6.8),43 tubular adenoma (OR¼ 3.6, 95% CI 1.9–6.4), and SSA/P (OR¼ 6.0, 95% CI 1.9–19.5).
CONCLUSIONS: The substantial prevalence of BRAF-mutated SSA/P and the independent association with synchronous
advanced colorectal neoplasia in asymptomatic average-risk subjects support the overall impact of the serrated pathway on
colorectal cancer (CRC) risk in general population. The endoscopic characteristics of SSA/P emphasize the need of high-quality
colonoscopy as a key factor for an effective CRC screening program.
Clinical and Translational Gastroenterology (2012) 3, e6; doi:10.1038/ctg.2011.5; published online 5 January 2012
Subject Category: colon/small bowel
INTRODUCTION
Serrated polyps (SPs) of the colon include hyperplastic polyps
(HPs), sessile serrated adenomas/polyps (SSA/P), and
traditional serrated adenoma (TSA).1 In contrast to adeno-
matous glands in conventional polyps, the presence of crypts
abnormalities such as ectopic crypt formation and compart-
mentalization seems to be a common denominator in all SPs
and different types can be distinguished based on these
events.2
SP nomenclature has been evolving during the last 10
years and even among expert pathologists there is significant
inter-observer variability in their classification. Most of
SSA/Ps were previously identified as HP before the histo-
logical differences between SSA/Ps and HPs were fully
appreciated. SSA/P account for up 20% of all serrated lesions
and are characterized by architectural distortion, with basal
crypt branching and dilation, serration, and horizontal
crypt orientation. SSA/P differ from TSA because their flat
morphology and lack of cytological dysplasia; other histo-
logical features of TSA include villiform configuration, eosino-
philic cytoplasm, and ectopic crypt formation.2,3
SSA/Ps are emerging as a new entity thought to be related
to colorectal adenocarcinoma by the ‘‘serrated pathway’’ of
colorectal cancer (CRC).4,5 This pathway is characterized by
early BRAF mutation, progressive DNA hypermethylation,
and the late development of microsatellite instability. Mole-
cular evidence has demonstrated that SSA/Ps are precursors
of CRC, especially microsatellite unstable CRC, which
account for approximately 15–20% of sporadic CRCs.4,5 In
addition, there is evidence that the presence of large SP is
associated with an increased risk of CRC and advanced
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colorectal neoplasia.6,7 Microvescicular HPs (MVHPs) and
goblet cell HPs represent different subtypes of HP, although
this distinction is not currently used in the standard clinical
practice. MVHP share with SSA/P frequent BRAF mutation
and CpG island methylator phenotype and have been
proposed to precede SSA/P in the serrated carcinogenesis;3
in contrast, goblet cell HPs usually display K-ras mutation and
whether they could represent precursor lesions in the serrated
pathway is unclear.
A review of the literature showed highly variable results in
the prevalence of SP, particularly for SSA/Ps. This variability
reflects inconsistent diagnostic criteria, inappropriate histo-
logical classification of different subtypes,8 variation in polyp
detection rate among endoscopists,9 application of enhancing
endoscopic modalities, and population selection criteria.10,11
Indeed, most of the data come from retrospective studies on
archive material without the possibility to define the endo-
scopic techniques applied or clinical indications. Findings
from only one small prospective study using chromoendo-
scopy are available but these are based on a patient
population presenting with large bowel symptoms and alarm
signs.11 No prospective data on average risk screening
population are available. Defining the true prevalence and
the clinical significance of different SP subtypes is crucial to
estimate the actual cancer risk posed by these lesions and to
formulate appropriate screening and surveillance strategies.
Recent studies have shown that large non-dysplastic SPs,
mainly HP and SSA/P, are associated with advanced neo-
plasia and CRC in screening colonoscopies.6,7 However, in
these studies serrated lesions were not well categorized and
therefore the association between different type of SPs and
advanced colonic neoplasia could not be determined.
The aims of this study were to prospectively determine the
prevalence and characteristics of SP subtypes, define their
mutation profile, and the association between each subtype
with synchronous advanced neoplasia in a large cohort of
asymptomatic average risk subjects undergoing first-time
colonoscopy.
METHODS
Subjects and study design. This single center prospective
study was conducted at the regional hospital of Feltre, Italy.
Ethical approval was obtained by the local institutional review
board. The study cohort was composed of consecutive
average-risk patients who underwent first-time colonoscopy
between June 2007 and December 2008. Patients agedZ50
years were recruited as part of the regional screening
program; patients aged o50 years were recruited in colla-
boration with community general practitioners who provided
information about the study. Eligibility was assessed by the
study investigators in a preliminary consultation and those
who gave their consent were included. Exclusion criteria
included alarm symptoms of disease of the lower gastro-
intestinal tract (recent onset of abdominal pain that normally
would require medical evaluation, change in bowel habits),
unexplained weight loss, occult anemia, rectal bleeding, and
previous colonoscopy performed for any reason; minor
abdominal discomfort and/or bloating were not considered
as exclusion criteria. Patients with family history of CRC or
adenomatous polyps, personal history of inflammatory bowel
disease, hereditary non-polyposis CRC, familial and hyper-
plastic polyposis, previous colonic resection were excluded.
Additional exclusion criteria were an unsatisfactory colonic
preparation (‘‘poor’’, see below) precluding a complete
examination. Smoking status was categorized in three
groups, never, former, and current smoker.
Colonoscopy and colonic neoplasms. Polyethylene
glycol solution (4 l) or sodium phosphate solution (90ml) was
taken orally 24 h before the procedure as standard bowel
preparation. The quality of bowel preparation was rated by the
endoscopist as ‘‘excellent,’’ ‘‘good,’’ ‘‘fair,’’ or ‘‘poor’’ based on
prespecified criteria (excellent: no or minimal stool residue,
small amount of clear fluid; good: minimal semisolid stool,
large amount of fluid; fair semisolid stool debris cleared after
suctioning; poor: solid stool and semisolid debris that cannot
be cleared). All procedures were performed by four
experienced gastroenterologists. Midazolam, meperidine,
and propofol were used for sedation. All the procedures
were performed using high-definition colonocopes (Olympus
CF-H180AL with 1080i HDTV signal, Olympus Italy, Milan,
Italy). Total time, withdrawal time, and examination time
(withdrawal time minus time needed for polypectomy, suction-
ing if applicable) were recorded. Colonic neoplasms were
characterized according to the Paris Endoscopic Classifi-
cation (protruding sessile (Is) and protruding pedunculated (Ip)
neoplasms; non-protruding superficial elevated (IIa), flat (IIb),
and depressed (IIc) neoplasms);12 endoscopic images were
reviewed and criteria agreed among endoscopists before
study initiation. In this study, all the non-protruding neoplasms
(IIa, IIb, IIc) were categorized as ‘‘flat’’.
It was also agreed among the investigators that all polyps,
even diminutive (size o5mm), should be removed and
retrieved. For purposes of the analysis, the junction of the
splenic flexure and the descending colon, as determined by
the endoscopist, defined the border between the proximal and
the distal colon.
The instrument used for polypectomy was either the cold
snare or electrocautery, depending on the size of the polyp
and personal preference of the endoscopist. The size of the
polyp was estimated with the use of the open-biopsy forcep
method. Each polyp resected was submitted in a separate jar
for pathological evaluation and molecular characterization.
Pathological findings. All colorectal polyps were reviewed
by two experienced gastrointestinal pathologists (RB and
GS). CRC included invasive cancer and Tis (carcinoma
in situ, intramucosal) category of TNM classification. Con-
ventional adenomas were classified as tubular, tubulovillous,
and villous adenoma with low or high grade of dysplasia
according to the degree of dysplasia. An advanced neoplasm
was defined as a large tubular adenoma (at least 1 cm in
maximal diameter), a polyp with villous features, a polyp with
high-grade dysplasia, or a cancer. SPs were classified as HP
(subdivided in MVHP and goblet cell-rich-type HP according
to the mucin content), SSA/P, SSA/P with cytological dys-
plasia, and TSA using the system described by Snover.3 HPs
were characterized by saw-toothed appearance in the upper
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part of the crypt and normal proliferative zone to the base of the
crypt. SSA/Ps were distinguished from HPs by the presence
of exaggerated serration, horizontally oriented and dilated
crypt bases, and increased proliferation. TSA showed villiform
protuberant configuration, serrated epithelial architecture,
ectopic crypt foci, eosinophilic cytoplasm in association with
features of conventional dysplasia (nuclear crowding and
enlargement, pencillate nuclei). SSA/P with cytological
dysplasia (SSA/P/DIS) comprised a sessile serrated architec-
ture component and a dysplastic component resembling
conventional adenomas. Where there was initial agreement
on the diagnosis by both pathologists, the polyp was included
without further review. In cases with an initially discordant
diagnosis, the polyps were reviewed by the two pathologists
together and discussed in an attempt to reach consensus.
During the consensus review, special attention was given to
the distinctive appearance of extensively dilated and/or hori-
zontally oriented basal crypts, and proliferation pattern. When
at least two relevant architectural features were confirmed, the
polyp was classified as SSA/P, otherwise as HP.
Molecular characterization
DNA extraction. Genomic DNA was extracted from 5–8mm
thick formalin-fixed, paraffin-embedded sections as
previously described.13 Briefly, after deparaffinization and
microdissection, lesional tissue was scraped and digested in
50–100ml buffer containing 50mM Tris-HCl pH 8.5, 1mM
EDTA pH 8.0, 0.5% (v/v) Tween–20, and proteinase K to a
final concentration of 3.3mg/ml. Digestion was carried out by
incubating samples at 55 1C for 16 h with gentle agitation.
After proteinase K inactivation at 95 1C for 10min and
centrifugation at room temperature for 10min, genomic
DNA in the supernatant was recovered and then quantified
using a conventional spectrophotometer.
BRAF and K-ras mutational analysis. BRAF (V600E) and
K-ras codon 12 and 13 mutational analysis were performed
using 200–500ng of the recovered DNA for PCR ampli-
fication. For assessing BRAF codon 600 status, a 174-bp
fragment was amplified using the following primer pair: 50-TG
TTTTCCTTTACTTACTACACCTCA-30 (forward) and 50-TTG
AGGCTATTTTTCCACTGA-30 (reverse) (Sigma, St Louis,
MO). A total of 50 cycles were performed at an annealing
temperature of 56 1C. The amplification program consisted of
five cycles of 1min each step followed by 45 cycles of 30 s
each step. The annealing temperature was 56 1C. Whenever
the amplification product was not visible after agarose gel
electrophoresis and ethidium bromide staining, a second
PCR round of 40 cycles was performed using 1 ml of the
amplification mixture. For K-ras codon 12 and 13, a fragment
of 190 bp was generated in the first PCR reaction, using the
following primer pair: 50-TTAACCTTATGTGTGACATGTT
CT-30 (forward) and 50-CAAGATTTACCTCTATTGTTGG
AT-30 (reverse) (Sigma, Poole, UK). PCR cycling was the
same as that used for BRAF analysis. If the amplification
product was not well visible after the electrophoretic run,
1–2ml of the PCR product was used as a template to amplify
a 171-bp nested fragment using the forward primer from the
first reaction together with the 50-TGGATCATATTCGTCCA
CAA-30 reverse primer. The annealing temperature was set
to 55 1C for both PCR rounds. PCR products were purified
from a low-melting agarose gel by means of the Qiaquick gel
Extraction kit according to the manufacturer’s protocol
(Qiagen, Crawley, West Sussex, UK). Purified DNA samples
were then sequenced (BMR Genomics, Padova, Italy).
Statistical analysis. Descriptive statistics showing the
percentage distribution of the different characteristics
by the explanatory variables were produced. Medians and
ranges are presented for continuous variables and
proportions for categorical variables. Differences between
variables were assessed by w2 analysis. All P values were
two-sided and considered significant wheno0.05. Predictors
of SP detection and the association between SPs, adeno-
matous polyps, and advanced neoplasia were assessed
by odds ratio (OR) with 95% confidence intervals (CI). ORs
were adjusted for gender, age (as a continuous variable),
smoking habit, SP subtype through multiple logistic regres-
sion equations. Data management and analysis were
performed using SPSS version 15 (SPSS, Chicago, IL).
RESULTS
A total of 985 individuals (median age 53 years, interquartile
range 43–66 years) who met the inclusion criteria were
consecutively enrolled. Among these 38% were men. The
mean total procedure time was 23.1±6.4min, examination
time 6.9±1.3min. Colorectal polyps were detected in 26.1%
subjects. A total of 263 polyps were found and resected, of
which 258 (98%) had complete histology; 155 (60%) were
adenomas and 39 (15%) had advanced histology. When
considering the morphology, 92 adenomas (59.3%) were
classified as protruding (5.8% peduncolated, 53.5% sessile)
and 63 adenomas (40.6%) as flat (39.3% superficial elevated,
1.3% flat). SP was the second most common polyp type,
comprising 40% (102 polyps) of all polyps. One polyp was
classified as hamartomatous (0.3%). Invasive CRC was
diagnosed in three patients (0.3%). The adenoma detection
rate (ADR) in the whole population was 14.8%, whereas in
subjects aged more than 50 years the ADR was 20.3% (ADR
in male 28.3%, ADR in female 16.4%).
Prevalence and characteristics of SPs subtypes. The
overall prevalence of SSA/P and TSA was 2.3% and 0.6%,
respectively. Characteristics of polyps and categorization
according to histology are shown in Table 1. Among SPs,
66.6% (n¼ 68) were diagnosed as HP, 27.4% (n¼ 28) as
SSA/P, and 5.8% (n¼ 6) as TSA. Forty-seven SP were
detected in the proximal colon (18.2% of all polyps) with a
proximal SP detection rate of 10.4%. Inter-observer agree-
ment measured by the Cohen’s k score for SP was strong
(k¼ 0.83, Po0.001). As expected, the main source of
inter-observer variability was in distinguishing SSA/P and
HP. SSA/Ps account for 10.8% of all polyps; their endoscopic
appearance was protruding sessile in 13 (46.4%; Figure 1)
and non-protruding (superficial elevated or flat) in 15
(53.5%). SSA/Ps were predominantly small (96.4% of
lesions were r10mm) with a mean size of 5.8±3.1mm,
similar to conventional adenoma (mean size 6.3±1.3mm)
but larger than HP (mean size 4.3±2.3mm). SSA/Ps were
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larger in the proximal colon compared with distal colon (mean
size 5.9±1.3mm vs. mean size 3.8±2.2mm, Po0.001).
Five SSA/P (18%) showed cytologic dysplasia. TSAs were
located predominantly in the left colon (75%) and appear
as protruding lesions (Figure 2), without differences in size
between proximal and distal locations (P¼ 0.5). Male gender
(OR¼ 1.9, 95% CI 1.1–4.8), increasing age (OR¼ 4.7, 95%
CI 1.0–21.8 for 50–69 years, OR¼ 7.3, 95% CI 1.5–35.4 for
70 or more years) and current smoking (OR¼ 3.9, 95% CI
1.4–10.6) were associated with the presence of either SSA/P
or TSA. Increasing age and current smoking but not gender
and former smoking were found to be independent predictors
of SSA/P by multivariate analysis (Table 2). When the
analysis included only patients with SSA/P and those with
normal colonoscopy, we found a higher risk of SSA/P asso-
ciated with current smoking (OR¼ 5.2, 95% CI 1.5–17.8).
Moreover, when compared with patients with tubular
adenoma, current smokers were nearly three times more
Table 1 Prevalence, location, and size of polyps according to histology
Histology Subjects (%; n¼ 220) Number (n¼ 258) Location (%) Size (%)
Proximal Distal r5mm 6–9mm Z10mm
Hyperplastic 45 (4.5) 68 29 (42) 39 (58) 61 (89.8) 6 (8.8) 1 (1.4)
MVHP 20 (2.0) 28 10 (36) 18 (64) 22 (78.6) 5 (17.8) 1 (3.6)
GCHP 25 (2.5) 40 19 (45) 21 (55) 38 (95) 2 (5) 0
SSA/P 23 (2.3) 28 16 (63.6) 12 (36.4) 21 (75) 6 (21.4) 1 (3.6)
TSA 5 (0.5) 6 2 (25) 4 (75) 2 (33.3) 3 (50) 1 (16.7)
Adenoma 146 (14.8) 155 66 (42.5) 89 (57.5) 103 (66.5) 34 (21.9) 18 (11.6)
Tubular 116 (11.8) 125 56 (44.8) 69 (55.2) 93 (74.4) 24 (19.2) 8 (6.4)
Tubulovillous 28 (2.8) 28 8 (28.6) 20 (71.4) 10 (35.8) 9 (32.1) 9 (32.1)
Villous 2 (0.2) 2 1 (50) 1 (50) 0 1 (50) 1 (50)
Hamartomatous 1 (0.1) 1 0 1 (100) 1 (100) 0 0
GCHP, goblet cells hyperplastic polyp; MVHP, microvescicular hyperplastic polyp; SSA/P, sessile serrated adenoma/polyp; TSA, traditional serrated adenoma.
Figure 1 Endoscopic (a) and histological features (b) of sessile serrated adenoma/polyp (SSA/P). SSA/Ps were predominantly small protruding sessile lesions,
with a layer of adherent mucus on the surface. Histology shows serrated features with horizontally oriented and dilated crypt bases (boot-shape).
Figure 2 Endoscopic (a) and histological features (b) of traditional serrated adenoma (TSA). TSAs were usually larger than 5 mm and showed protruberant growth pattern.
Histological appearance showing serrated epithelial architecture in association with features of conventional dysplasia (nuclear crowding and pencillate nuclei).
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likely to have an SSA/P (OR¼ 2.8, 95% CI 1.3–8.5). Male
gender, age, current smoking, patients with three or more
tubular adenomas, and the presence of at least one either
SSA/P or TSA but not HP were significantly associated
with synchronous advanced adenoma. Multivariate analysis
confirmed that gender, age, current smoking, number of
tubular adenoma are significant risk factors and showed that
only the presence of SSA/P, but not TSA, was independently
associated with synchronous advanced adenoma (OR¼ 6.0,
95% CI 1.9–19.5; Table 3); this relationship was confirmed
even when SSA/P/DIS were removed (OR¼ 5.8, 95% CI
2.3–14.8). Harboring an SSA/P was associated with a higher
risk for advanced adenoma in the proximal compared with
distal colon (advanced adenoma proximal (OR¼ 8.05, 95%
CI 1.8–79) and distal (OR¼ 2.8, 95% CI 2.05–29.5)). The
proximal location of SSA/P showed a stronger association
with synchronous advanced adenoma (proximal SSA/P
(OR¼ 18, 95% CI 2.91–11.1), distal SSA/P (OR¼ 9.4, 95%
CI 2.8–31)).
Mutation profile of SP subtypes. The molecular features
of SPs are summarized in Table 4. Mutations of BRAF
(V600E) were found in 69.5% of SSA/P, in all SSA/P/DIS
and 40% of HP but in none of the TSAs. K-ras mutation
was present in all TSA. BRAF and K-ras mutations were
mutually exclusive in both SSA/Ps and HPs. There was no
relationship between BRAF mutation and either SSA/P and
SSA/P/DIS location or size. In contrast, BRAF mutation was
more common in left-sided MVHPs.
DISCUSSION
A primary goal of CRC screening is the detection and removal
of premalignant lesions, which may lead to cancer prevention.
Among different subtypes of SPs, SSA/P and TSA have been
recently recognized as the precursors of up to 20%of sporadic
CRC through the serrated-carcinoma pathway. Despite the
increasing knowledge on the categorization of SPs and the
progress in defining the molecular pathogenesis, data on
the real prevalence of SSA/P and TSA among average-risk
individuals are very limited. This study represents the first
prospective evaluation of the prevalence of different SP
subtypes in a large cohort of average-risk asymptomatic
subjects. We found that SSA/P account for 8.9% of all polyps
and 22.1% of SP, whereas only 1.5% of all polyps were TSA.
The reported proportion of SSA/P among all polyps in other
retrospective series ranged from 0.8 to 3.9%.9,10,14 This
variation can be explained by differences in the selected
population,9,11 in diagnostic threshold,15 and in the only
moderate inter-observer concordance.8 SSA/Ps have been
underdiagnosed formany years because of their resemblance
to HPs and recent data have shown that the proportion of
SSA/Ps that were initially unrecognized and misdiagnosed as
HPs ranged from 5 to 22%. Moreover, information regarding
the prevalence of SP from large retrospective, cross-sectional
studies often derived from database recorded before the
criteria for SSA/P had been established, without the possibility
of performing an analysis for different SP subtypes. The
higher concordance rate for SP subtypes reported in our study
can be explained by the pre-study agreement on diagnostic
criteria and the subspecialty training of our gastrointestinal
pathologists.8 In our population, the prevalence of SSA/P was
2.3%. Before this, only one retrospective study has included
patients undergoing colonoscopy for the indication of average
risk CRC screening and reported a lower proportion of SSA/P
and TSA (1.3% and 0.3% of all polyps detected, respectively)
Table 2 Relative risk estimates of SSA/P
MLR-OR (95% CI)
Sex
Female 1
Male 2.2 (0.9–5.7)
Age (years)
o50 1
50–69 5.8 (1.3–26.8)
Z70 9.3 (1.9–45.4)
Smoke
No 1
Former 2.6 (0.7–9.3)
Current 4.9 (1.5–16.4)
CI, confidence interval; MLR, multiple logistic regression; OR, odds ratio;
SSA/P, sessile serrated adenoma/polyp.
Table 3 Predictive factors for advanced colorectal neoplasia
MLR-OR (95% CI)
Sex
Female 1
Male 2.0 (1.0–4.0)
Age (years)
o50 1
50–69 4.5 (1.5–13.4)
Z70 9.9 (3.1–31.5)
Smoke
No 1
Former 1.4 (0.5–4.0)
Current 2.0 (1.3–6.8)
Adenomatous polyps
n43 3.6 (1.9–6.4)
SSA
No 1
Yes 6.0 (1.9–19.5)
CI, confidence interval; MLR, multiple logistic regression; OR, odds ratio;
SSA, sessile serrated adenoma.
Table 4 BRAF and K-ras mutation in different subtypes of serrated polyps
BRAF mutation (%) K-ras mutation (%)
Proximal Distal Proximal Distal
MVHP 4/10 (40) 10/18 (55.5) 0 0
GCHP 0 0 2/19 (10.5) 3/21 (14.2)
SSA/P 10/14 (71.4) 6/9 (66.6) 0 0
SSA/P/DIS 3/3 (100) 2/2 (100) 0 0
TSA 0 0 1/2 (50) 3/4 (75)
GCHP, goblet cells hyperplastic polyp; MVHP, microvescicular hyperplastic
polyp; SSA/P/DIS, sessile serrated adenoma with cytological dysplasia/polyp;
TSA, traditional serrated adenoma.
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with an overall prevalence of SSA/P of 0.6%.9 However, as
acknowledged by the authors, pathology misclassification,
variation in polyp detection rate among endoscopists and use
of standard white-light endoscopy represent limitations, which
may have underestimated the prevalence of SPs. These
aspects can explain the substantial lower rate of SSA in their
work compared with our study.
The percentage of SSA/P found in our population is similar
to that by Spring et al.11 who described a small group of
consecutive patients. However, in that study, subjects were
referred to colonoscopy for lower gastrointestinal-related
symptoms, or because a family history of CRC and surveil-
lance after CRC or polyp removal. We enrolled average-risk
individuals at their first colonoscopy, excluding patients with
symptoms and other factors that might have affected the
detection rates of colonic neoplasms. Thus, our findings are
more directly applicable to screening cohorts and may have
potential implications on the level of awareness endoscopists
should have on both the importance of these distinct lesions
and the willingness to remove them effectively.
Earlier studies have suggested that SSA/Ps are large
in size and occur predominantly in the proximal
colon.1,2,11,14,16,17 Although we confirmed that proximal
lesions appear larger,11 SSAs emerged to be predominantly
small with more than half being diminutive (r5mm). Inter-
estingly, in our study, SSAs were equally located between left
and right colon. These findings are consistent with those of
Lu et al.18 The differences with previous literature can be
explained in part by the fact that several studies often
excluded small specimens from the analysis due to inade-
quate material, poor orientation, or lack of agreement in the
distinction between HP and SSA/Ps. As the diagnosis of
SSA/P relies importantly on the morphology of basal crypts,
sample quality and orientation have a great impact on the
detection of the characteristic morphological features. It has
been shown that a correct classification of SP is difficult to
apply in tangentially cut, small, and fragmented lesions.16 In
our study, small size polyps were removed by cold snare
resection and when analyzed, the vast majority of these
samples contained well-oriented full-thickness mucosa.
Differences in the detection of SSA/Ps among studies
could also be related to different skills of endoscopists and
adherence to a ‘‘leave no polyp behind’’ approach, particularly
in the presence of diminutive polyps. Recently, Hetzel et al.9
have shown that detection rate of SSA/P and HP varied
significantly among endoscopists; this variability together with
the inter-pathologist discrepancy in SPs classification could
be responsible for the increasing trend of SSA/P detection
over the time shown in this study. In our prospective study, the
aimwas to remove all the polyps detected, including small and
diminutive polyps in distal colon. All procedures were
performed by experienced examiners; withdrawal time and
ADR did not vary among endoscopists and met the targets
established as quality indicators for screening colonoscopy.19
One limitation of our study is that chromoendoscopy was
not applied. SSA/Ps usually appear flat to sessile with a soft
smooth-appearing surface and are known to be best detected
by such technique.19 However, we have used high-definition
technology, which has been shown to improve the diagnostic
yield for superficially elevated, flat lesions.20
A second limitation is that we have an overall low ADR. Data
on ADR by high-definition white-light technology in average
risk individuals are available from only one recent study by
Kahi et al.21 Compared with this study, our lower ADR can
be explained by differences in our study population which
included only white, predominantly female and younger
subjects without family history of CRC or adenoma. Thus,
a third limitation could be the applicability of our findings
only in population with such geographical and epidemiological
characteristics. However, when patients younger than
50 years were removed, ADR was 28.3% in male and
16.4% in female, meeting the recommended threshold.19
Recently, the detection rate of SPs has been suggested as a
newmeasure of quality in colonoscopy.22 Indeed, in our study
the overall proportion of colonoscopies with the detection of at
least one proximal serrated lesion was similar (10.4 vs. 13%)
to what has been recently reported by Kahi et al.23 in a large
cohort of average risk patients.
Three recent studies have found an association between
the presence of large non-dysplastic SPs with synchronous
advanced neoplasia and proximal CRC.6,7,24 It is important to
note that in all these studies different subtypes of SP were not
categorized by histology and the precise association between
each type of SP and advanced neoplasia could not be
determined. A more recent retrospective study reported that
individuals who harbor SSA/P and adenomas have more
advanced pathology including cancer compared with patients
with adenoma only;25 however, patients with increased risk
or with family history were also present in the study cohort,
SSA/P cases included large HP and serrated lesions were
not histologically reviewed.26 In our study, we were able to
demonstrate for the first time that among average-risk
subjects harboring one SSA/P but not HP or TSA there was
an increased likelihood of synchronous advanced adenoma.
Moreover, we found that proximal SSA/Ps are associated with
higher rates of synchronous advanced adenomas, compared
with patients with distal SSA/Ps, irrespective of their size.
An inevitable drawback of our study, including screening
average-risk population, is that we could not provide further
information about the risk with synchronous CRC because of
the small proportion of patients affected.
The molecular characterization of SP in our study showed
the presence of BRAF mutation in a significant proportion of
distal small SSA/P. Our results agree with two other recent
studies where the presence of BRAF mutation was confirmed
in diminutive and distal SSA/P.10,27 The occurrence of BRAF
mutation in diminutive left-sided SSA/Ps is consistent with its
observation in the earliest steps of the serrated pathway such
as serrated hyperplastic aberrant crypt foci.28 MVHPs exhibit
morphological similarities with SSA/P, share high frequency of
BRAF mutations and are commonly detected in the distal
colon.3,29,30 We have confirm the presence of BRAF mutation
in nearly half of MVHPs regardless their location. These
findings suggest that MVHP and SSA/P probably represent
a spectrum of related lesions along the serrated neoplasia
pathway. In the present study, current smoking was indepen-
dently associated with the presence of SSA/P of any size or
location and we confirmed this relationship when patients with
SSA/P were compared with those with normal colonoscopy
andwith tubular adenomas. These findings are consistent and
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support what recently found by Anderson et al.31 in a
retrospective, case–control study. BRAF mutation has been
linked with smoking and observed in early precursors lesions
such as serrated aberrant crypt foci.32 Our findings are
consistent with earlier reports 33,34 and provide more data to
suggest that smoking may have a role in the development
of SPs. However, based on the current data, it is not possible
to predict or estimate the incremental effect of smoking on the
progression of non-dysplastic SPs to advanced lesions.
In our cohort, the less representative subtypes of SP were
TSAs (0.6%), consistent with the present literature,10,11,14
and K-ras mutation was found in the majority of TSAs. The
morphological characterization of TSAs has been only
recently redefined and associated with an alternate pathway
of sporadic colorectal carcinogenesis, molecularly characte-
rized by K-rasmutation and with left-side location.35 However,
in our study TSA did not significantly influence the risk of
synchronous advanced adenoma; this lack of associationmay
be related to the small number of reported cases.
Our results may have potential implications for CRC
screening. Given the malignant potential of the various types
of SP, with a conversion rate at least as great as that shown for
conventional adenomas, the clinical relevance of detection
and removal of SSA/P and TSA could be reflected in issues
such as high-quality baseline screening colonoscopy and
surveillance. Based on our findings, any SSA/P smaller than
10mm should be completely excised and followed up
endoscopically. In order to define appropriate SP surveillance
guidelines, we need to improve criteria to stratify the risk.
Longitudinal and follow-up studies will clarify how the SP
subtype and location influence this risk and also how the
importance of polyp number compares to that for conventional
adenoma.
As average-risk individuals account for almost 75% of
patients with CRC, detection and removal of precursor lesions
in this population provide the best opportunities for improving
cancer prevention effectiveness. Knowledge of prevalence of
SSA/P and TSA in this population will allow us to estimate the
true rate of malignant conversion of these lesions.
Our findings are that 14%of all polyps had serrated features
with malignant potential, the majority of which were small and
spread throughout the colon, provides strong evidence that all
such lesions should be completely removed and underline the
need for high-quality colonoscopy as a key factor for an
effective CRC-screening program.
The appropriate surveillance intervals following the removal
of such serrated lesion has yet to be established. Until
longitudinal studies have been conducted on progression and
recurrence of serrated lesions defined by standardized
nomenclature, it seems advisable to provide follow-up
surveillance to patients with SSA/P and TSA as the current
guidelines for conventional adenoma.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
| Approximately 10–20% of all colorectal cancer arises
through the serrated pathway.
| The reported prevalence of serrated polyps is highly
variable because of evolving nomenclature, population
selection criteria, and variation in detection rate among
endoscopists.
WHAT IS NEW HERE
| This is the first prospective study to examine the preva-
lence of different serrated polyp subtypes in asympto-
matic average-risk subjects undergoing first-time
colonoscopy.
| The prevalence of sessile serrated adenoma/polyps
(SSA/P) and traditional serrated adenoma (TSA) was
2.3% and 0.6%, respectively.
| Current smoking was significantly associated with the
presence of SSA/P.
| Subjects harboring one SSA/P had an increased like-
lihood of synchronous advanced adenoma, irrespective
of size.
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